Topical cyclosporin A at a 2% concentration was used for 6 months in the management of 2 patients with vernal keratoconjunctivitis who had failed to respond to conventional therapy. We used one drop every 6 hours in both eyes during the first month and every 12 hours during the remaining 5 months. Clinical controls were carried out weekly during the first month, montbly during the 6 month period and every 2 months thereafter. Cyclosporin A blood levels and sernm creatinine were regularly monitored in both patients. 
were carried out weekly during the first month, montbly during the 6 month period and every 2 months thereafter. Cyclosporin A blood levels and sernm creatinine were regularly monitored in both patients. We consider that topical cyclosporin A represents an important addition to the therapeutic armamen tarium because it is effective in controlling the symptoms and signs of vernal keratoconjunctivitis and seems to be well tolerated both locally and systemically.
